Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Jul 2, 2024

31100_dirs_2024-07-02_2dd6ae3b-3a89-441f-a9d0-2255bc35d0b8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-07-01

Reporting Person: PICKERING GRANT (Director, CHIEF EXECUTIVE OFFICER)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-07-01 Common Stock S 674 $75.8446 Disposed 144072 Indirect
2024-07-01 Common Stock S 634 $76.8586 Disposed 143438 Indirect
2024-07-01 Common Stock S 751 $75.9205 Disposed 143995 Indirect
2024-07-01 Common Stock S 557 $76.8868 Disposed 143438 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 478888 Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.43 to $76.25. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.435 to $77.125. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.43 to $76.285. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.

F6: Shares are held directly by a trust for the benefit of the Reporting Person's son.

F7: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.435 to $77.155. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.